ArticleExpert opinion on pharmacotherapy2011
The ACQUIRE trial.
Article in Expert opinion on pharmacotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achievement of goal blood pressure values, particularly in high-risk categories of patients, still remains an unmet goal of the therapeutic approach to hypertension. The same conclusion can be drawn for patient adherence to antihypertensive drugs, which is a variable of major relevance for obtaining optimal blood pressure control in treated hypertensives. The ACQUIRE study has recently evaluated the efficacy and safety profile of either aliskiren monotherapy or aliskiren/hydrochlorothiazide combination treatment in a consistent number of stage 2 hypertensive patients, half of them complicated by obesity. The results show the effectiveness of aliskiren, particularly when combined with hydrochlothiazide, in achieving satisfactory blood pressure control. This is particularly the case for systolic blood pressure values, which have a major detrimental impact on cardiovascular risk profile and on cardiovascular events. The combination drug regimen, which can achieve early blood pressure control, was accompanied by an excellent side-effect and safety profile and thus was associated with a high adherence to treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.